Prosecution Insights
Last updated: November 20, 2026
Application No. 19/048,816

GINGEROL COMPOSITIONS AND RELATED METHODS

Final Rejection §103§112
Filed
Feb 07, 2025
Priority
Feb 08, 2024 — provisional 63/551,486 +1 more
Examiner
ARNOLD, ERNST V
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
ThermoLife International LLC
OA Round
4 (Final)
48%
Grant Probability
Moderate
5-6
OA Rounds
1y 4m
Est. Remaining
61%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
674 granted / 1399 resolved
-11.8% vs TC avg
Moderate +13% lift
Without
With
+12.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
59 currently pending
Career history
1484
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
43.1%
+3.1% vs TC avg
§102
16.0%
-24.0% vs TC avg
§112
19.8%
-20.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1399 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claim 4 is cancelled. Claim 33 is new. Claims 1-3 and 5-33 are pending. Claims 16-30 are withdrawn. Claims 1-3, 5-15 and 31-33 are under examination. Applicants’ amendment has necessitated new ground of rejection. Accordingly, this Action is FINAL. Withdrawn rejections Applicants’ amendments and arguments filed 8/18/26 are acknowledged and have been fully considered. The Examiner has re-weighed all the evidence of record. Any rejection and/or objection not specifically addressed below is herein withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of rejections and/or objections presently being applied to the instant application. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 33 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Determining the adequacy of a written description "requires an objective inquiry into the four comers of the specification from the perspective of a person of ordinary skill in the art." Id. Thus, "[I]psis verbis disclosure is not necessary to satisfy the written description requirement of Section 112." Fujikawa v. Wattanasin, 93 F.3d 1559, 1570 (Fed. Cir. 1996). In the instant case, the claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 33 introduces new matter as the claim recites the limitation: "at least about 14% by weight 6-gingerol”. Applicant directs the Examiner to Table 1 for support. Table 1 is: PNG media_image1.png 292 926 media_image1.png Greyscale The specification discloses “14-20%” of 6-gingerol, which has hard end-points but does not describe the instantly claimed limitation which requires “at least about 14% by weight 6-gingerol”. The term “at least about” is reasonably interpreted to mean “at least” or “about” 14% by weight 6-gingerol. The specification states: “As used herein, the term "about" refers to a deviation no more than 10% of the given value”. Consequently, the claimed limitation includes values below 14% by weight, which is outside the range in Table 1 and constitutes new matter. Consequently, there is no support in the specification for this limitation. There is no guidance in the specification to select “at least about 14% by weight 6-gingerol”. Therefore, it is the Examiner’s position that the disclosure does not reasonably convey that the inventor had possession of the subject matter of the amendment at the time of filing of the instant application. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-3, 5-10, 14 and 31-33 are rejected under 35 U.S.C. 103 as being unpatentable over Verburgh et al. (US20230085573; IDS filed 8/7/25) and Bredesen et al. (WO2014025905; of record) and Ganio (US20220105128) and Applied Food Sciences ([online] retrieved on 2/13/26 from: https://appliedfoods.com/beverage-expert-applied-food-sciences-makes-breakthrough-with-two-new-launches-in-organic-ingredients/; 2016: 8 pages). This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103. Applicant claims, for example: PNG media_image2.png 336 1184 media_image2.png Greyscale PNG media_image3.png 144 1094 media_image3.png Greyscale PNG media_image4.png 184 1138 media_image4.png Greyscale Claim interpretation: The scope of claim 1 includes aqueous solutions in which the water-soluble reaction product would be soluble to at least about 10 mg/L, which is 0.01 mg/mL. That means that the ionic components that form the reaction product are present and the scope of claim 1 includes those embodiments. Level of Ordinary Skill in the Art (MPEP 2141.03) MPEP 2141.03 (I) states: “The “hypothetical ‘person having ordinary skill in the art’ to which the claimed subject matter pertains would, of necessity have the capability of understanding the scientific and engineering principles applicable to the pertinent art.” Ex parte Hiyamizu, 10 USPQ2d 1393, 1394 (Bd. Pat. App. & Inter. 1988). The level of skill is that of a nutritional/dietary research scientist, as is the case here, then one can assume comfortably that such an educated artisan will draw conventional ideas from nutritional compounds and their application to treat diseases/conditions, pharmaceutical formulation methods and techniques, human physiology and general chemistry— without being told to do so. In addition, the prior art itself reflects an appropriate level (MPEP 2141.03(II)). Determination of the scope and content of the prior art (MPEP 2141.01) Regarding claims 1, 5, 13-14 and 32-33, Verburgh et al. teach compositions comprising 1 mg lithium and 80 mg ginger extract (Claims 1, 2 and 9), that contains at least 2% gingerols [0019], where at least 2% is open ended and overlaps “at least about 14% by weight” limitation of claim 33, with a pharmaceutically acceptable carrier (Claim 14) and can be formulated for delayed release or extended release (Claims 11-13; [0022]). Verburgh et al. guide the artisan to PurGinger™ from Applied Food Sciences [0019]. As taught by Applied Food Sciences, PurGinger™ is a powdered organic ginger extract that is highly water soluble and clear in solution (Page 3, 1st paragraph). Verburgh et al. teach that the pharmaceutically acceptable carriers are “well known to those skilled in the art. For example, oral delivery systems include, for example, tablets, capsules, and powders (such as powders that can be added to water to form a drinkable formulation).” [0013] Thus, the composition of Verburgh et al. is for human ingestion. Verburgh et al. teach: “Preferably, the present composition ( e.g., the embodiments described in this paragraph) is in the form of a powder that, when admixed with a fluid such as water, can be taken orally as a drink by the subject (preferably once daily).” [0021] An oral drink is suitable for human ingestion. It is the Examiner’s position that admixture of the composition in powder form in water provides the water-soluble reaction product the extract of ginger with a source of lithium that naturally has a solubility in water of greater than 100 mg/mL (instant claim 13) and the composition has a solubility in water of at least about 10 mg/L. The same water-soluble components dissolved in water will have the same solubility in the absence of evidence to the contrary. Indeed, Applicant’s own claimed method of making the reaction product is to simply provide the extract of ginger and mix with a source of lithium to produce a water-soluble form of ginger extract (Claim 23). No special conditions or steps are required. Regarding claim 7, Verburgh et al. also teach dosage ranges of: 1 mg of micro-dosed lithium (or optionally, any of 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, or 2.0 mg) and 80 mg of ginger extract (or optionally, any of 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 70 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1,000 mg) [0032]. Thus, the composition can have 1 mg of a source of lithium and 100 mg of ginger extract for a weight ratio of 1:100. Regarding claim 10, Verburgh et al. teach “excipients such as binders (e.g., hydroxypropylmethyl-cellulose, polyvinylpyrrolidone, other cellulosic materials and starch), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulosic materials), disintegrating agents ( e.g., starch polymers and cellulosic materials) and lubricating agents (e.g., stearates and talc). In one embodiment, the oral delivery system is a powder and comprises one or more of xylitol, malic acid, flavoring, silicon dioxide, calcium silicate, and roadside A.” [0013] Verburgh et al. teach: “the present composition comprises one or more sweeteners such as, without limitation, erythritol, trehalose, maltitol, mannitol, sorbitol, xylitol, isomalt, lactitol, tagatose, monk fruit, inuline, and stevia-derived substances.” [0021] In addition to those food additives, claims 1-8 also add food additives such as vitamin C and glucosamine. Regarding claim 31, how the ginger extract is obtained such as by total CO2 liquid, reads on a product-by-process type limitation. Please note that in product-by-process claims, “once a product appearing to be substantially identical is found and a 35 U.S.C. 102/103 rejection [is] made, the burden shifts to the applicant to show an unobvious difference.” See MPEP 2113 Product-by-Process Claims [R-08.2017] I. PRODUCT-BY-PROCESS CLAIMS ARE NOT LIMITED TO THE MANIPULATIONS OF THE RECITED STEPS, ONLY THE STRUCTURE IMPLIED BY THE STEPS Further regarding claim 32, the ginger extract of Verburgh et al. naturally contains the one or more active compounds claimed. Regarding claims 1-2, Bredesen et al. disclose a composition comprising the element lithium, which reads on metallic lithium, and ginger (Claims 1-2), which contains all the active components contained in an extract of ginger, in a single combined formulation (Claim 42) and is inherently fit for human ingestion. Bredesen et al. provide an example with water soluble ionic salt form lithium carbonate, which is the from the weak acid carbonic acid (Page 29). Bredesen et al. distinguish between elements, chemical compounds, minerals and salts (Page 22, lines 19-29; Page 23, Table 1) with lithium salts, such as lithium carbonate, orotate, chloride and aspartate, as sub-types of the element lithium (Page 23, Table 1). Regarding claim 7, Bredesen et al. disclose that the lithium is present in at least about 1 mg and the ginger is present in at least about 100 mg (Claim 36), thus providing a ratio of at least about 1:100. Claim 37 of Bredesen et al. discloses about 1-20 mg of lithium and about 100-1000 mg ginger. Regarding claims 1-3, Ganio renders obvious elemental lithium, lithium hydroxide, lithium hydride, lithium orotate, lithium aspartate, lithium chloride and lithium carbonate [0025] for administration to a human subject (Abstract; Claims 1-6 and 10). Formulations include dispersions, suspensions, powders and liquid sprays [0026-0028]. Ascertainment of the difference between the prior art and the claims (MPEP 2141.02) and Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143) The difference between the instant application and Verburgh et al. is that Verburgh et al. do not expressly teach a reaction product formed in aqueous solution with 6-gingerol that has a solubility of at least about 10 mg/L or greater than 100 mg/mL or that the source of the lithium comprises one or more of metallic lithium or the charged lithium species lithium hydroxide or lithium hydride in an amount of at least 0.1% by weight with the total concentration of active compounds in the composition being at least about 1000 micromole/L and the pH of the solution is 8-14. The deficiency in Verburgh et al. is cured by the teachings of Bredesen et al., Applied Food Sciences and Ganio. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to make the composition of Verburgh et al. with a reaction product formed in aqueous solution with 6-gingerol that has a solubility of at least about 10 mg/L or greater than 100 mg/mL, as suggested by Applied Food Sciences, and where the source of the lithium comprises one or more of metallic lithium or the charged lithium species lithium hydroxide or lithium hydride, as suggested by Bredesen et al. and Ganio, in an amount of at least 0.1% by weight with the total concentration of active compounds in the composition being at least about 1000 micromole/L and the pH of the solution is 8-14, and produce the instant invention. One of ordinary skill in the art would have been motivated to do this because of the following rationale. First regarding the solubility of the reaction product in aqueous solution, Verburgh et al. guide the artisan to using a highly water soluble extract of ginger to begin with in combination with lithium and admixed with water. It stands to reason that the highly water soluble extract of ginger in combination with lithium forms a reaction product in the aqueous solution with a solubility of at least about 10 mg/L and greater than 100 mg/mL. The extract of ginger naturally contains 6-gingerol and the range of at least 2% overlaps the claimed range of at least about 14% by weight. This is merely selection of a known compound (6-gingerol) and optimization of the amount with a reasonable expectation of success. Secondly, Verburgh et al. is open to all sources of lithium including metallic/elemental lithium an and charged ionic lithium such as lithium hydroxide or lithium hydride. The art of Bredesen et al. renders obvious at least elemental/metallic lithium the lithium salts lithium carbonate, orotate, chloride and aspartate to combine with ginger. Ganio teach the functional equivalence of lithium hydride and lithium hydroxide with elemental lithium, lithium carbonate, lithium orotate, lithium chloride and lithium aspartate. Thus, the art teaches that these are known alternatives for the same desired function of providing lithium and obvious over one another. "The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results." KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 417 (2007). Moreover, “Where two known alternatives are interchangeable for a desired function, an express suggestion to substitute one for the other is not needed to render a substitution obvious." In re Fout 675 F.2d 297, 301 (CCPA 1982). Consequently, having elemental/metallic lithium or lithium hydride or lithium hydroxide in the composition of Verburgh et al. is obvious over the combined references. Regarding the amount of at least 0.1% by weight and the total concentration of active compounds in the composition being at least about 1000 micromole/L, such is readily optimized by the ordinary artisan to achieve the desired outcome with a reasonable expectation of success in the absence of evidence to the contrary. Especially when Verburgh et al. provide ranges of amounts of the ingredients to employ. Regarding the pH range of 8-14, since the same components are employed and Verburgh et al. as modified by Bredesen et al., then it is merely taking a pH meter and measuring the resulting pH of the solution. The ordinary artisan would do so with a reasonable expectation of success. The difference between the instant application and Verburgh et al. is that Verburgh et al. do not expressly teach all the forms of instant claim 14. However, Verburgh et al. teach that the compositions can be formulated using one or more routinely used pharmaceutically acceptable carriers [0013] and “means to deliver the agent to a subject’s body via any known method.” [0012] The claimed forms of instant claim 14 are common and conventional routinely used forms for compositions in this art to deliver an agent to the subject’s body. The ordinary artisan in this art can readily formulate the composition of Verburgh et al. with the appropriate carrier to produce a tablet, capsule, a solution, an elixir, a syrup, a tincture, a suspension, an emulsion, a mouth wash, a spray, a drop, an ointment, a cream, a gel, a paste, a suppository, a pessary, a cream, a gel, or a foam with a reasonable expectation of success. Claims 11, 12, 131 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Verburgh et al. (US20230085573) and Bredesen et al. (WO2014025905) and Ganio (US20220105128) and Applied Food Sciences ([online] retrieved on 2/13/26 from: https://appliedfoods.com/beverage-expert-applied-food-sciences-makes-breakthrough-with-two-new-launches-in-organic-ingredients/; 2016: 8 pages), as applied to claims 1-3, 5-10, 14 and 31-33, in further view of Zhong et al. (CN1751596A; of record) and Zhou et al. (Molecules 2023;28(7562):16 pages; of record). Applicant claims: PNG media_image5.png 194 1086 media_image5.png Greyscale PNG media_image6.png 98 1098 media_image6.png Greyscale The references of Verburgh et al., Bredesen et al., Ganio and Applied Food Sciences are discussed in detail above. As noted above Verburgh et al. suggest a capsule embodiment [0013]. Further regarding claims 11, 12 and 15, Bredesen et al. teach and suggest that the formulations for oral use can be soft capsules with liquid polyethylene glycols (Page 54, lines 1-8). Regarding claims 11, 12 and 15, Zhou et al. teach that: “Polyethylene glycol 400 (PEG400) is a widely used pharmaceutical excipient in the field of medicine. It not only enhances the dispersion stability of the main drug but also facilitates the absorption of multiple drugs.” (Abstract) And: “PEG 400 is one of the very few polymers approved for injection. Due to its good solubilization and absorption-promoting effects, PEG400 is widely used in oral administration and skin and mucosa applications, especially in TCM soft capsules. It has unique advantages as it provides good dispersion and stabilization effects on the main drug while promoting intestinal drug absorption.” (Page 2, 2nd paragraph). Soft capsules read on softgels. Regarding claims 11, 12 and 15, Zhong et al. teach soft capsules comprising ginger and PEG400 (Claims 1, 3, 7; embodiments 5-7). Soft capsules read on softgels. Ascertainment of the difference between the prior art and the claims (MPEP 2141.02) and Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143) The difference between the instant application and Verburgh et al. as modified by Bredesen et al. is that Verburgh et al. as modified by Bredesen et al., Ganio and Applied Food Sciences does not teach adding PEG400 to the composition. This deficiency in Verburgh et al. as modified by Bredesen et al., Ganio and Applied Food Sciences is cured by the teachings of Zhou et al. and Zhong et al. It would have been obvious to one of ordinary skill in the art prior to the effective filing date of the claimed invention to add PEG400, as suggested by Zhou et al. and Zhong et al., to the composition of Verburgh et al. as modified by Bredesen et al., Ganio and Applied Food Sciences, and produce the instant invention. One of ordinary skill in the art would have been motivated to do this because to practice the capsule embodiment of Verburgh et al. the artisan must select some sort of capsule and Bredesen et al. direct the artisan to soft gelatin capsules that contain polyethylene glycols. Not only is PEG400 a commonly used pharmaceutical excipient in the field of medicine well-known to the ordinary artisan as taught by Zhou et al. but also Zhong et al. guides the artisan to PEG400 for softgel compositions comprising ginger. Since Verburgh et al. is open to adding pharmaceutically acceptable excipients [0013], then it is obvious to add the widely used pharmaceutical excipient PEG400 in at least the softgel embodiment of the combined references with a reasonable expectation of success. In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a). From the combined teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the combined references, especially in the absence of evidence to the contrary. Response to Arguments Applicant’s arguments are repetitive and regurgitated from previous arguments and have been carefully considered but are not persuasive. The Examiner’s previous responses are incorporated by reference. Applicant asserts: “Claim 1 does not recite a solution in which ionic components are merely present. It recites "the water-soluble reaction product of' an extract of ginger and a source of lithium, "wherein the reaction product is formed in an aqueous solution." The Examiner strongly disagrees. The specification teaches in [0087]: “within 10 min of drinking 2 ml of the preparation produced in Example 1 with 8 oz of water”. Aqueous solutions are within the scope of the claims. Applicants’ arguments are not persuasive. On pages 7-8 of remarks, Applicant asserts that “The Examiner's suggestion (Office Action at 6) that Applicant's claimed method of making the reaction product is merely to "provide the extract of ginger and mix with a source of lithium" and that"[ n ]o special conditions or steps are required" respectfully misconstrues the chemistry. The mixing step recited in withdrawn Claim 23…is simple to perform”. Applicant names no special conditions or steps but rather admits it “is simple to perform”. Applicants’ argument is not persuasive. Applicant asserts: “The Office Action Inherency Argument Is Legally Insufficient and Is Factually Contradicted by the Experimental Evidence of Record”. Applicant bases their fallacy on: “Because Verburgh does not teach forming any reaction product with lithium-and indeed does not specify any particular form of lithium-the prior art simply does not establish, expressly or inherently, the claimed reaction product.” However, both species are present in aqueous conditions and if it works for Applicant then it must also work for Verbough. Applicant has failed to demonstrate otherwise. Applicants’ arguments are not persuasive. On pages 9-10, Applicant argues that: “The experimental evidence of record affirmatively disproves inherency.” Applicant discusses Example 2 and Example 9. However, in Example 2 and Example 9 there is no experimental evidence that disproves inherency as found in Examiner's reasoned response to this evidence (Office Action at 17-20). On this point, there is no agreement. On page 10, Applicant continues with: “the recited solubility is a property of the reaction product, not of the starting materials, and no applied reference discloses that reaction product.” But since the prior art teaches the combination in aqueous solution then the same solubility is present. Applicants’ arguments are not persuasive. Applicant argues that ThermoFischer Scientific Safety Data Sheet undermines the rejection. First, ThermoFischer is not an applied reference in the rejection and cannot undermine the rejection. Secondly the Examiner stated: “Moreover, the Examiner has serious concerns about the safety of such a composition for human ingestion comprising lithium hydroxide as in Example 9. In no uncertain terms the Safety Data Sheet for lithium hydroxide (ThermoFisher Scientific Safety Data Sheet created 2010, revised 2025; 9 pages) expressly teaches that it is harmful if swallowed and to call a physician or poison control center immediately if ingested because of possible perforation of the stomach or esophagus (Pages 1-3 of the Safety Data Sheet). The Safety Data Sheet states: “Do not ingest.” (Page 4 top). The Examiner has serious safety concerns about Applicants composition for human ingestion. Applicants’ argument are not persuasive. On pages 11-12, Applicant argues that: “only the specifically claimed lithium sources (metallic Li, Li OH, LiH) produced the recited solubilization of the ginger extract”. The Examiner addressed this previously: “Respectfully, this is an expected result. Extracts of ginger are based on a phenol structure as shown in Figure 1 of Shahrajabian et al. (Acta Agriculturae Scandinavica, Section B — Soil & Plant Science 2019; 12 pages) below: PNG media_image7.png 476 1044 media_image7.png Greyscale It is commonly known chemistry that phenol compounds react with metal or strong bases like NaOH to form phenoxide salts which enhance their solubility shown below from the chapter on Alcohols and Phenols ([online] retrieved on 2/12/26 from: 7.4 Alcohols and Phenols | NCERT 12 Chemistry; 4 pages): PNG media_image8.png 638 874 media_image8.png Greyscale PNG media_image9.png 466 854 media_image9.png Greyscale The reaction with an alkali metal, such as sodium or lithium, or a strong base such as NaOH or LiOH, is expected to deprotonate the water insoluble phenol to form the polar phenoxide ion which increases solubility in aqueous solution. This is exactly what applicant observed in Example 9 where weakly basic compounds lithium citrate, lithium ascorbate and lithium lactate had no notable dissolution but lithium hydroxide dissolved the phenol containing ginger extract. The fact that citric acid did not convert the phenoxide back to phenol lies in the fact that citric acid is a weak acid. Applicant should try a strong acid like hydrochloric acid or sulfuric acid to precipitate the phenol.” Applicant contends: “The Examiner's reliance on Bredesen' s tabular reference to "element lithium" to render obvious metallic lithium (Claim 2) similarly fails.” The Examiner has addressed this argument previously in the last Office Action and it was not persuasive then and it is not persuasive now. On this point, there is no agreement. Arguments concerning new claim 33 have been considered but are not persuasive as claim 33 is rejected above as being obvious. Applicant argues that: “Claims 8 and 9 recite, respectively, that the composition comprises an amount of lithium in uncharged or ionic form of at least 0.1 % by weight, and that the concentration of active compounds is at least about 1000 micromole/L. The Office identifies no reference disclosing or suggesting either value. It states only that such amounts are readily optimized by the ordinary artisan to achieve the desired outcome with a reasonable expectation of success in the absence of evidence to the contrary. Office Action at 10-11. That is legally insufficient.” The Examiner did address those claim limitations and Applicant has failed to demonstrate any criticality of the amount or concentration. The Examiner has a similar response for claims 6 and 7. Applicants’ arguments are not persuasive. Regarding claim 13, Applicant asserts that: “Claim 13 depends from Claim 11…The first-stated rejection therefore does not address every limitation of Claim 13.” However, the second stated rejection does address the limitation of claim 11 and the subject matter of claim 13 is discussed in the first stated rejection and incorporated into the second rejection and consequently all limitation of claims 11 and 13 have been addressed. Applicants’ argument is not persuasive. Applicant argues that the rationale for the PEG 400 and softgel limitations is fatally circular. That is wrong. The Examiner articulated a reasonable rationale: “to practice the capsule embodiment of Verburgh et al. the artisan must select some sort of capsule and Bredesen et al. direct the artisan to soft gelatin capsules that contain polyethylene glycols. Not only is PEG400 a commonly used pharmaceutical excipient in the field of medicine well-known to the ordinary artisan as taught by Zhou et al. but also Zhong et al. guides the artisan to PEG400 for softgel compositions comprising ginger. Since Verburgh et al. is open to adding pharmaceutically acceptable excipients [0013], then it is obvious to add the widely used pharmaceutical excipient PEG400 in at least the softgel embodiment of the combined references with a reasonable expectation of success.” Applicants’ arguments are not persuasive. Arguments concerning Examples 2 and 9 have been addressed. Applicant further argues that: “Claim 31 does not recite a process; it identifies a specific source material for the ginger extract. The total CO2 liquid ginger extract is a well-defined commercial product with a characteristic composition.” However, claim 31 describes how the ginger extract was obtained with CO2 liquid. If Applicant desires a particular composition, then Applicant should amend the claim. Applicant points to Example 8 where conventional total CO2 liquid ginger extract was tested against the inventive composition. However, conventional total CO2 liquid ginger extract is not water-soluble and therefore the results are expected. Applicant’s arguments are not persuasive. Applicant argues: “The Examiner's explanation accounts for some of what is observed (deprotonation of phenols by strong bases) but cannot explain why NaOH and KOH fail while LiOH succeeds, or why weak-acid lithium salts fail while strong-base/highly-reactive lithium sources succeed.” Wrong. The rationale provided by the Examiner explains why. From the Examiner’s standpoint, there are absolutely no unexpected results and Applicants’ assertion that “the unexpected results of Examples 2, 8, and 9 constitute objective evidence of nonobviousness” is entirely unsupported with factual evidence. Applicants’ arguments are not persuasive. The Examiner has only applied facts and sound reasoning to reject the claimed subject matter. Hindsight was not employed. None of Applicants’ arguments are persuasive. Conclusion No claims are allowed. Applicants’ amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERNST V ARNOLD whose telephone number is (571)272-8509. The examiner can normally be reached M-F 7-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian Y Kwon can be reached at 571-272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERNST V ARNOLD/Primary Examiner, Art Unit 1613 1 Claim 13 was inadvertently included in the first rejection. The limitations of claim 13 were described in the first rejection and met in the second 103 rejection here. All claim limitations were met.
Read full office action

Prosecution Timeline

Show 2 earlier events
Oct 22, 2025
Response Filed
Nov 06, 2025
Final Rejection mailed — §103, §112
Jan 23, 2026
Request for Continued Examination
Jan 29, 2026
Response after Non-Final Action
Feb 18, 2026
Non-Final Rejection mailed — §103, §112
Aug 18, 2026
Response Filed
Sep 30, 2026
Response Filed
Oct 26, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797343
IMPROVED PATCH
3y 5m to grant Granted Nov 17, 2026
Patent 12797333
METHOD FOR PREPARING PROTEIN MICROBEADS FOR IMPROVING STABILITY OF PROTEIN PREPARATION
3y 3m to grant Granted Nov 17, 2026
Patent 12758500
PHARMACEUTICAL COMPOSITION FOR IMPROVING RESPIRATORY DAMAGE AND USE FOR MANUFACTURING PHARMACEUTICAL COMPOSITION FOR IMPROVING RESPIRATORY DAMAGE
2y 7m to grant Granted Oct 13, 2026
Patent 12758580
METHOD FOR MAKING AGED NANOCOMPOSITE
2y 1m to grant Granted Oct 13, 2026
Patent 12740999
A SOLID-GAS REACTION TO GENERATE NITROXYL (HNO) IN THE GAS PHASE
2y 10m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
48%
Grant Probability
61%
With Interview (+12.6%)
3y 2m (~1y 4m remaining)
Median Time to Grant
High
PTA Risk
Based on 1399 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month